{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.05","upperLimit":"3.75","value":"2.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"EBV positive related gastric cancer"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.84","upperLimit":"6.93","value":"3.25"},{"groupId":"OG001","lowerLimit":"1.77","upperLimit":"6.80","value":"3.71"},{"groupId":"OG003","lowerLimit":"1.77","upperLimit":"7.39","value":"3.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"HPV positive SCCHN"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"1.94","upperLimit":"14.29","value":"4.63"},{"groupId":"OG002","lowerLimit":"2.04","upperLimit":"7.49","value":"3.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Other anogenital HPV associated cancers"},{"categories":[{"measurements":[{"comment":"Upper limit not calculable as upper CI bound does not cross 50% threshold","groupId":"OG004","lowerLimit":"1.08","upperLimit":"NA","value":"1.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"title":"SCCHN I-O naive"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.87","upperLimit":"9.07","value":"5.09"},{"groupId":"OG001","lowerLimit":"3.32","upperLimit":"9.23","value":"3.75"},{"groupId":"OG002","lowerLimit":"3.71","upperLimit":"17.25","value":"7.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"45"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Randomized"},{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"3.75","upperLimit":"9.03","value":"5.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"112"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Cervical, Pooled"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.22","upperLimit":"8.15","value":"3.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"Vaginal/Vulvar"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.20","upperLimit":"62.52","value":"21.32"},{"groupId":"OG001","lowerLimit":"3.71","upperLimit":"24.34","value":"8.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"43"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"MCC"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.54","upperLimit":"3.58","value":"1.94"},{"groupId":"OG001","lowerLimit":"2.37","upperLimit":"9.23","value":"5.36"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"title":"NPC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"195"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"}],"units":"Participants"}],"description":"Investigator-assessed progression free survival (PFS) is defined as the time from first dosing date to the date of the first documented tumor progression, as determined by investigators (per RECIST 1.1), or death due to any cause, whichever occurs first. Participants with the following diseases will be assessed:\n\n1. EBV positive related gastric cancer;\n2. HPV positive SCCHN;\n3. Other anogenital HPV associated cancers;\n4. GYN (Cervical, Vaginal, Vulvar) carcinoma;\n5. Merkel cell carcinoma (MCC);\n6. Nasopharyngeal carcinoma (NPC) Note: \"Cervical, Randomized\" and \"Cervical, Pooled\" are not mutually exclusive categories","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab IV over 30 minutes at 240 mg every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG000","title":"Metastatic Monotherapy"},{"description":"Nivolumab 3 mg/kg IV over 30 minutes every 2 weeks + Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG001","title":"Metastatic Combo A"},{"description":"Nivolumab 1 mg/kg IV over 30 minutes + Ipilimumab 3 mg/kg IV over 30 minutes every 3 weeks for 4 doses followed by Nivolumab 240 mg IV over 30 minutes every 2 weeks for a maximum of 24 months or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG002","title":"Metastatic Combo B"},{"description":"Nivolumab 240 mg IV over 30 minutes + BMS-986016 (Relatlimab) 80 mg IV over 60 minutes administered every 2 weeks for a maximum of 24 months, or until disease progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG003","title":"Metastatic Combo C"},{"description":"Daratumumab 16 mg/kg IV weekly for the first 8 weeks. Starting at Week 3, Nivolumab 240 mg IV over 30 minutes every 2 weeks. Daratumumab 16 mg/kg every 2 weeks from Weeks 9-24. Starting at Week 25, Nivolumab 480 mg IV flat dose over 30 minutes every 4 weeks; daratumumab 16 mg/kg every 4 weeks for a maximum of 24 months or until progression, unacceptable toxicity, or withdrawal of consent, whichever comes first","id":"OG004","title":"Metastatic Combo D"}],"paramType":"MEDIAN","populationDescription":"All treated participants in the metastatic cohorts","reportingStatus":"POSTED","timeFrame":"From the first dosing date to the date of the first documented tumor progression or death due to any cause, whichever occurs first (Up to 83 months)","title":"Metastatic: Investigator-Assessed Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}